TRVD™

Heart failure (HF) is a pandemic affecting millions of people worldwide. Although the vast majority of hospitalizations for worsening HF are due to symptoms of congestion and volume overload, patients are frequently discharged with residual signs of congestion, which likely contribute to the consistently high readmission rates observed in acute decompensated heart failure (ADHF).

The kidneys are the primary organs responsible for maintaining the body’s water and salt balance. As encapsulated organs, they are particularly vulnerable to congestion: cardiac dysfunction and fluid buildup/redistribution leads to increased central venous pressure, increased renal venous pressures and, ultimately, increased renal interstitial pressures. The latter result in decreased renal blood flow, glomerular filtration rate, urine output and sodium excretion.

These cardio-renal interactions lead to fluid retention and vasoconstriction, further aggravating the syndrome in a reinforcing feedback loop. Other than diuretics, there are no major therapies currently available for this complex patient population. Indeed, there is an urgent clinical need, as well as an important opportunity, for a novel HF therapy to reduce readmission rates, improve clinical outcomes and reduce costs.

The Transcatheter Renal Venous Decongestion (TRVD™) System is designed to reduce the pressure in both renal veins (and hence in the venous outlet of the kidneys) employing a safe, simple, and elegant catheter-based approach. An axial-flow pump-head is positioned in the inferior vena cava (IVC), while two sealing elements are positioned above and below the kidneys to compartmentalize the renal segment of the IVC and allow selective reduction of renal venous pressures. The TRVD™ System is intended to be placed shortly following hospital admission, for a period of 1-3 days, in order to mechanically unload the kidneys as early as possible, preserve and improve kidney function, and promote diuresis and natriuresis in a physiological manner.

The TRVD™ System is not yet commercially available in any jurisdiction.

TRVD™

Heart failure (HF) is a pandemic affecting millions of people worldwide. Although the vast majority of hospitalizations for worsening HF are due to symptoms of congestion and volume overload, patients are frequently discharged with residual signs of congestion, which likely contribute to the consistently high readmission rates observed in acute decompensated heart failure (ADHF). The encapsulated kidneys, which are the primary organs responsible for maintaining the body’s water and salt balance, are particularly vulnerable to congestion: the increased central venous pressure secondary to cardiac dysfunction and fluid buildup/redistribution increases renal venous pressure, which, in turn, decreases renal blood flow, glomerular filtration rate, and sodium excretion. These cardio-renal interactions lead to fluid retention and vasoconstriction, further aggravating the syndrome in a reinforcing feedback loop. Currently, no major therapies are available other than diuretics, hence there is an urgent clinical need, as well as an important opportunity, for a novel HF therapy to reduce readmission rates, improve clinical outcomes and reduce costs.

The Transcatheter Renal Venous Decongestion (TRVD™) System is designed to reduce the pressure on both renal veins (and hence in the venous outlet of the kidneys) employing a safe, simple, and elegant catheter-based approach. An axial-flow pump-head is positioned in the inferior vena cava (IVC), while two sealing elements are positioned above and below the kidneys to compartmentalize the renal segment of the IVC and allow selective reduction of renal venous pressures. The TRVD™ System is intended to be placed shortly following hospital admission, for a period of 1-3 days, in order to mechanically unload the kidneys as early as possible, preserve and improve kidney function, and promote diuresis and natriuresis in a physiological manner.

Scroll to top